WEBULL

Assessing Cabaletta Bio (CABA) Valuation as ESGCT Data Drives New Attention to Rese-cel Clinical Progress

Simply Wall St · 10/12/2025 17:17

Recent data presented at the ESGCT Congress put the spotlight on Cabaletta Bio (CABA), as its investigational CAR T therapy, rese-cel, showed strong B cell depletion and positive early clinical responses in pemphigus vulgaris patients, even without preconditioning.

See our latest analysis for Cabaletta Bio.

Following the news from the ESGCT Congress, Cabaletta Bio's share price jumped more than 26% over the past month, as investors responded enthusiastically to initial RESET-PV trial data and renewed pipeline momentum. Despite the strong recent move, the 1-year total shareholder return is still down nearly 45%, reminding us that while optimism is returning, the long game will be shaped by regulatory milestones and further clinical progress.

If novel immunotherapies like this have you intrigued, it is a promising moment to explore the latest breakthroughs with our See the full list for free.

With the recent surge in share price and a price target far above current levels, the real question is whether Cabaletta Bio remains a hidden value play or if the market is already factoring in future success.

Price-to-Book Ratio of 1.2x: Is it justified?

Trading at a price-to-book ratio of 1.2x, Cabaletta Bio stands out as notably cheaper than both its US Biotechs peers and the broader market, with a last close of $2.32.

The price-to-book ratio compares a company's market value to its book value, giving investors insight into how much they are paying for each dollar of net assets. In high-growth biotech, low ratios reflect uncertainty about near-term profitability but can also highlight unloved pipeline potential.

Cabaletta’s 1.2x ratio is meaningfully more attractive than the US Biotechs industry average of 2.5x and the peer group average of 30.9x. Such a deep discount signals that the market is either overlooking future prospects or remains unconvinced by the clinical pipeline. However, recent trial developments may start changing sentiment.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book Ratio of 1.2x (UNDERVALUED)

However, disappointing future trial data or regulatory setbacks could quickly reverse recent gains and change investor expectations for Cabaletta Bio's outlook.

Find out about the key risks to this Cabaletta Bio narrative.

Another View: Discounted Cash Flow Says Deep Value

Looking through a different lens, the SWS DCF model estimates Cabaletta Bio’s fair value at $35.13, which is dramatically higher than the current price of $2.32. This suggests the market might be missing significant upside. However, how reliable are such projections for early-stage biotech stocks?

Look into how the SWS DCF model arrives at its fair value.

CABA Discounted Cash Flow as at Oct 2025
CABA Discounted Cash Flow as at Oct 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cabaletta Bio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Cabaletta Bio Narrative

If you want to dig deeper, the data is yours to explore and your own perspective might reveal something new. Why not shape your own narrative in a matter of minutes? Do it your way

A great starting point for your Cabaletta Bio research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t miss your chance to get ahead of the crowd. Simply Wall Street’s powerful screeners are some of the fastest ways to find your next breakthrough stock idea.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.